Prometheus and Long­board make the leap to Nas­daq with 9-fig­ure of­fer­ings and are joined by a Fal­con Edge-backed SPAC

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

It’s been hard to match the whirl­wind first two months of the year in terms of IPO mo­men­tum, and March so far has been rel­a­tive­ly qui­et on that front. But that doesn’t mean com­pa­nies aren’t tak­ing the leap — now, two more biotechs and a SPAC are hop­ping aboard the train.

Fron­tier Ac­qui­si­tion, a SPAC led by Fal­con Edge Cap­i­tal’s Rick Ger­son, took home the largest raise at $200 mil­lion, fol­lowed close­ly by Prometheus Bio­sciences with $190 mil­lion. And Long­board Phar­ma­ceu­ti­cals se­cured an $80 mil­lion jump on­to Nas­daq, just over four months af­ter launch­ing out of Are­na Phar­ma­ceu­ti­cals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.